Acute Lymphoblastic Leukemia Registry at Asan Medical Center

Study Overview
=================
Brief Summary
-----------------
The investigators would like to propose a prospective longitudinal observational cohort study for patients who will be diagnosed and/or treated for acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, to use the acquired data for fundamentals of other retrospective analysis.

Detailed Description
-----------------
Acquisition of informed concent form Data acquisition from medical record including demographic / disease-associated factors details of treatment, and its results complications during treatment genetic data survival outcome (upto 10 years) Accumulation of data for 30 years Use of data for other retrospective analysis (including Asan Medical center Cell Banking basic data)

Official Title
-----------------
Prospective Observational Cohort Registry for Patients With Acute Lymphoblastic Leukemia at Asan Medical Center

Conditions
-----------------
Leukemia, Acute Lymphoblastic, Precursor B-Cell Lymphoblastic Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Lymphoblastic Lymphoma

Intervention / Treatment
-----------------
* Other: Diagnosed as ALL


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients who are diagnosed and/or treated as acute lymphoblastic leukemia at Asan Medical Center (including biphenotypic acute leukemia with Philadelphila-positive, Burkitt leukemia/lymphoma) 15 years of age and over All patients who give written consent according to guidelines at Asan Medical Center committee on human research Exclusion Criteria: Patients who refuse to give consent to registering

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ph-ALL<br>Diagnosed as ALL with Philadelphia-negative | Other: Diagnosed as ALL<br>* All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047<br>* Other names: Diagnosed as acute lymphoblastic leukemia;|
| Ph+ALL<br>Diagnosed as ALL with Philadelphia-positive (including biphenotypic acute leukemia with Philadelphia-positive) | Other: Diagnosed as ALL<br>* All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047<br>* Other names: Diagnosed as acute lymphoblastic leukemia;|
| Other ALL<br>Diagnosed as ALL of other type, including Burkitt leukemia | Other: Diagnosed as ALL<br>* All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047<br>* Other names: Diagnosed as acute lymphoblastic leukemia;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | 10 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Event-free survival | Definition of events will be as 'relapse', 'death from any cause'. Relapse will be defined as hematologic relapse and molecular relapse, respectively when the patient is diagnosed as Philadelphia-positive acute lymphoblastic leukemia | 10 years | 
| Relapse-free survival | Relapse will be defined as hematologic relapse and molecular relapse, respectively when the patient is diagnosed as Philadelphia-positive acute lymphoblastic leukemia | 10 years |